Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

The National Cancer Institute, a component of the National Institutes of Health, has issued a funding opportunity titled Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) under the funding opportunity number PA-25-172. This reissued notice invites applications for research within the broad scope of cancer control and population sciences. The overarching goal is to promote novel scientific ideas that can substantially advance cancer research in various areas, including statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, healthcare delivery, digital health and data science, and implementation science. The funding initiative responds to heightened competition for research grants, increased costs of research, and barriers faced by early-stage investigators (ESIs). It aligns with priorities under the NIH Next Generation Researchers Initiative and the 21st Century Cures Act, aiming to foster opportunities for new researchers and earlier research independence. This opportunity emphasizes research that can be conducted within shorter timeframes and reduced budgets, thus providing a supportive avenue for ESIs. Eligible applicants include a wide range of U.S. and non-U.S. organizations, such as higher education institutions, nonprofits, for-profit organizations, tribal organizations, local governments, and foreign entities. Individuals with the necessary skills and resources are invited to apply. There is no cost-sharing requirement. Applicants may submit multiple scientifically distinct applications, and foreign components are allowed. Applications must adhere strictly to the guidelines provided in the NIH Application Guide. Required components include the use of NIH ASSIST, Grants.gov Workspace, or institutional system-to-system solutions for submission. Detailed application instructions cover required registrations, form content, budget limitations, and data sharing requirements. The application must include human subjects information if applicable and may only include limited appendix materials. Applications are reviewed based on significance, innovation, rigor, feasibility, and expertise of the investigators and environment. The review process involves scientific peer review followed by advisory council review. Funding decisions consider scientific merit, available funds, and program priorities. Contact points for scientific and financial inquiries are provided. Key dates include an opening date of January 5, 2025, with standard NIH submission cycles continuing through 2027. The expiration date is January 8, 2028. There are no specific pre-application deadlines or letters of intent required. Applications are due by 5:00 PM local time on specified dates within each cycle.